Ana A. P.
- Country
- Spain
- Department
- 172413: Hematology and Hemotherapy
Research Overview
- Phase 1 Evaluation of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase Mutations
- Phase 1 Open-Label Dose Escalation and Expansion Study of CLN-049 in Acute Myeloid Leukemia with Measurable Residual Disease
- Evaluation of JNJ-74856665 in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Data & Insights
Has run more than one trial at 181 of 346 partner sites.
Specializations
Myeloid Disorders
The investigator specializes in treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with particular focus on novel therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- Higher-risk MDS treatment strategies
- IDH1 mutation targeted therapies
- NPM1-mutated AML interventions
Research extends to studying hypomethylating agent combinations and targeted molecular therapies for myeloid malignancies.
Hematologic Malignancies
Active involvement in developing treatments for various blood cancers, including B-cell non-Hodgkin lymphoma and multiple myeloma.
- Novel immunotherapy approaches
- Combination therapy strategies
- Relapsed/refractory disease management
Expertise includes evaluation of innovative therapeutic agents and cellular therapies for hematologic disorders.
Anemia Management
Focuses on treating anemia in lower-risk MDS patients, particularly investigating novel approaches for those who are refractory to standard treatments.
- Erythroid response optimization
- Transfusion dependency reduction
- Ring sideroblast MDS treatment
Specializes in developing therapeutic strategies for patients with transfusion-dependent anemias.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.